Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy IART Stock  Free IART Stock Alerts

Integra LifeSciences (IART) Financials

Integra LifeSciences logo
$12.75 -0.53 (-3.99%)
Closing price 04:00 PM Eastern
Extended Trading
$12.74 -0.01 (-0.04%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Integra LifeSciences

Annual Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 34 -3.52 75 65 61 50 134 169 181 68 -6.94
Consolidated Net Income / (Loss)		 34 -3.52 75 65 61 50 134 169 181 68 -6.94
Net Income / (Loss) Continuing Operations		 36 6.85 75 65 61 50 134 169 181 68 -6.94
Total Pre-Tax Income 		46 61 90 11 57 60 94 215 214 81 -18
Total Operating Income		 68 80 115 45 111 94 151 197 239 112 28
Total Gross Profit		 494 556 643 753 901 953 851 945 970 885 882
Total Revenue		 797 883 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611
Operating Revenue		 797 883 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611
Total Cost of Revenue		 303 327 349 436 571 565 521 598 587 657 728
Operating Cost of Revenue		 303 327 349 436 571 565 521 598 587 657 728
Total Operating Expenses		 426 477 528 708 790 859 700 747 731 773 854
Selling, General & Admin Expense		 376 416 456 624 691 688 595 637 616 657 717
Research & Development Expense		 44 51 58 63 78 144 77 93 101 104 115
Amortization Expense		 6.81 9.95 14 20 21 27 28 17 14 12 21
Total Other Income / (Expense), net		 -22 -19 -25 -33 -54 -34 -58 17 -25 -30 -47
Interest Expense		 22 24 26 35 65 54 72 50 50 51 71
Interest & Investment Income		 0.17 0.03 0.02 0.26 2.80 11 9.30 6.74 12 17 20
Other Income / (Expense), net		 -0.49 4.59 0.85 1.35 8.29 9.52 4.43 61 13 3.72 3.94
Income Tax Expense		 9.27 54 16 -53 -3.40 9.90 -40 46 33 13 -11
Basic Earnings per Share		 $0.52 ($0.05) $1.00 $0.84 $0.73 $0.59 $1.58 $2.00 $2.18 $0.85 ($0.09)
Weighted Average Basic Shares Outstanding		 64.86M 68.99M 74.39M 76.90M 82.86M 85.64M 84.65M 84.70M 83.00M 80.09M 77.01M
Diluted Earnings per Share		 $0.52 ($0.05) $0.94 $0.82 $0.72 $0.58 $1.57 $1.98 $2.16 $0.84 ($0.09)
Weighted Average Diluted Shares Outstanding		 65.92M 71.35M 79.19M 79.12M 84.00M 86.49M 85.23M 85.49M 83.52M 80.34M 77.01M
Weighted Average Basic & Diluted Shares Outstanding		 32.40M 70.40M 74.60M 77.10M 83.30M 84.44M 84.37M 83.24M 81.64M 78.22M 77.22M

Quarterly Income Statements for Integra LifeSciences

This table shows Integra LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 50 53 24 4.18 19 20 -3.28 -12 -11 19
Consolidated Net Income / (Loss)		 50 53 24 4.18 19 20 -3.28 -12 -11 19
Net Income / (Loss) Continuing Operations		 50 53 24 4.18 19 20 -3.28 -12 -11 19
Total Pre-Tax Income 		59 64 30 3.82 19 29 -5.23 -15 -20 23
Total Operating Income		 65 68 36 13 27 36 3.96 -3.03 -8.15 36
Total Gross Profit		 237 250 233 207 218 226 207 226 200 249
Total Revenue		 385 398 381 381 382 397 369 418 381 443
Operating Revenue		 385 398 381 381 382 397 369 418 381 443
Total Cost of Revenue		 148 148 148 174 164 171 162 192 181 194
Operating Cost of Revenue		 148 148 148 174 164 171 162 192 181 194
Total Operating Expenses		 172 182 196 195 192 190 203 229 208 213
Selling, General & Admin Expense		 144 152 167 165 162 163 166 195 177 179
Research & Development Expense		 25 27 27 27 27 24 27 30 27 31
Amortization Expense		 3.14 3.54 3.11 3.03 3.21 3.03 10 3.71 3.76 3.72
Total Other Income / (Expense), net		 -6.25 -3.63 -6.60 -8.68 -7.98 -7.19 -9.19 -12 -12 -13
Interest Expense		 13 13 12 12 13 14 14 19 19 19
Interest & Investment Income		 3.26 5.31 4.11 3.94 4.61 4.55 5.04 5.06 5.05 4.89
Other Income / (Expense), net		 3.29 3.95 1.39 -0.16 0.47 2.01 -0.61 1.44 2.11 1.01
Income Tax Expense		 8.88 11 5.55 -0.36 -0.89 9.02 -1.95 -2.78 -9.67 3.11
Basic Earnings per Share		 $0.60 $0.65 $0.30 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25
Weighted Average Basic Shares Outstanding		 83.04M 83.00M 81.87M 80.97M 79.69M 80.09M 77.74M 77.41M 76.45M 77.01M
Diluted Earnings per Share		 $0.60 $0.63 $0.29 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25
Weighted Average Diluted Shares Outstanding		 83.40M 83.52M 82.32M 81.15M 79.81M 80.34M 77.74M 77.41M 76.45M 77.01M
Weighted Average Basic & Diluted Shares Outstanding		 83.52M 81.64M 81.90M 81.40M 78.18M 78.22M 78.80M 77.58M 77.16M 77.22M

Annual Cash Flow Statements for Integra LifeSciences

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -49 -24 54 73 -31 60 271 43 -57 -180 -30
Net Cash From Operating Activities		 84 105 116 115 200 231 204 312 264 140 129
Net Cash From Continuing Operating Activities		 63 117 116 115 200 231 204 312 264 140 129
Net Income / (Loss) Continuing Operations		 36 6.85 75 65 61 50 134 169 181 68 -6.94
Consolidated Net Income / (Loss)		 34 -3.52 75 65 61 50 134 169 181 68 -6.94
Depreciation Expense		 46 59 73 89 111 109 116 120 118 124 141
Amortization Expense		 2.57 2.26 2.53 2.72 6.27 5.39 12 - 6.85 6.16 5.59
Non-Cash Adjustments To Reconcile Net Income		 23 60 -16 31 27 99 46 10 23 23 47
Changes in Operating Assets and Liabilities, net		 -45 -11 -18 -73 -5.22 -32 -105 13 -64 -81 -58
Net Cash From Investing Activities		 -363 -372 -43 -1,221 -50 -163 -68 -161 -59 -94 -391
Net Cash From Continuing Investing Activities		 -360 -365 -43 -1,221 -50 -163 -68 -161 -59 -94 -391
Purchase of Property, Plant & Equipment		 -38 -33 -47 -44 -78 -70 -39 -48 -42 -67 -104
Acquisitions		 -321 -329 - -1,242 0.00 -96 -25 -304 -56 0.00 -288
Purchase of Investments		 - - - - 0.00 1.58 -7.84 0.00 4.91 -27 -53
Sale of Property, Plant & Equipment		 0.00 1.44 0.32 0.29 0.42 0.04 3.66 0.00 11 0.00 0.00
Divestitures		 - 0.00 0.00 46 27 0.00 0.00 190 24 0.00 0.00
Sale and/or Maturity of Investments		 - 0.00 0.00 17 0.91 0.75 - 0.08 0.00 0.00 55
Net Cash From Financing Activities		 239 248 -15 1,169 -181 -8.77 122 -98 -252 -230 238
Net Cash From Continuing Financing Activities		 239 295 -15 1,169 -181 -8.77 122 -98 -252 -230 238
Repayment of Debt		 -199 -470 -701 -136 -665 -246 -465 -126 -149 -118 -187
Repurchase of Common Equity		 - - - - 0.00 0.00 -100 0.00 -125 -275 -52
Issuance of Debt		 425 545 680 1,307 171 237 747 26 41 165 487
Other Financing Activities, net		 12 0.72 5.63 -2.01 -37 0.43 -104 2.02 -19 -1.55 -9.04
Other Net Changes in Cash		 - - - 11 - 0.07 - - -11 3.89 -6.46

Quarterly Cash Flow Statements for Integra LifeSciences

This table details how cash moves in and out of Integra LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 65 -55 -149 1.83 -35 2.67 316 -377 -0.08 31
Net Cash From Operating Activities		 68 85 26 28 27 59 16 40 22 51
Net Cash From Continuing Operating Activities		 68 85 26 28 27 59 16 40 22 51
Net Income / (Loss) Continuing Operations		 50 53 24 4.18 19 20 -3.28 -12 -11 19
Consolidated Net Income / (Loss)		 50 53 24 4.18 19 20 -3.28 -12 -11 19
Depreciation Expense		 29 29 31 31 31 31 31 37 36 38
Amortization Expense		 1.75 1.70 1.89 1.42 1.42 1.43 1.40 1.46 1.34 1.40
Non-Cash Adjustments To Reconcile Net Income		 10 -2.22 4.86 5.68 5.93 6.64 13 14 3.66 17
Changes in Operating Assets and Liabilities, net		 -23 3.41 -36 -14 -31 -0.15 -26 0.44 -7.77 -24
Net Cash From Investing Activities		 15 -55 -14 -16 -7.70 -57 -54 -322 -10 -4.25
Net Cash From Continuing Investing Activities		 15 -55 -14 -16 -7.70 -57 -54 -322 -10 -4.25
Purchase of Property, Plant & Equipment		 -9.16 -14 -14 -16 -13 -25 -15 -30 -30 -30
Acquisitions		 - -52 - - - - - - - -5.77
Purchase of Investments		 - - 0.00 - 5.38 -33 -39 -10 - -4.13
Sale and/or Maturity of Investments		 - - - - - - - - - 35
Net Cash From Financing Activities		 -7.64 -98 -163 -11 -50 -6.89 359 -94 -20 -7.15
Net Cash From Continuing Financing Activities		 -7.64 -98 -163 -11 -50 -6.89 359 -94 -20 -7.15
Repayment of Debt		 -18 -108 -20 -17 -57 -25 -15 -91 -42 -40
Repurchase of Common Equity		 - - -150 - -125 - 0.00 -50 - -2.47
Issuance of Debt		 11 6.50 10 5.00 132 18 371 59 22 35
Other Financing Activities, net		 -1.14 3.60 -2.91 1.01 0.44 -0.09 3.28 -12 -0.17 -0.14
Other Net Changes in Cash		 - 12 0.94 -0.21 -4.87 8.04 -4.96 -1.13 7.75 -8.12

Annual Balance Sheets for Integra LifeSciences

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 1,587 1,774 1,808 3,211 3,108 3,303 3,615 3,782 3,890 3,782 4,037
Total Current Assets		 529 438 495 822 775 858 1,237 1,154 1,161 1,058 1,082
Cash & Equivalents		 72 48 102 175 139 199 470 513 457 276 246
Short-Term Investments		 - - - - - - - - 0.00 33 27
Accounts Receivable		 110 132 148 252 266 275 226 232 263 259 272
Inventories, net		 189 211 217 296 280 316 310 317 325 390 429
Prepaid Expenses		 28 43 28 99 90 68 69 91 86 67 77
Other Current Assets		 - - - - - - - - 31 33 30
Plant, Property, & Equipment, net		 194 205 222 269 300 337 288 312 311 340 406
Total Noncurrent Assets		 864 1,131 1,090 2,120 2,033 2,108 2,090 2,317 2,417 2,384 2,550
Goodwill		 363 512 511 938 926 954 932 1,013 1,039 1,055 1,097
Intangible Assets		 413 604 561 1,160 1,079 1,032 989 1,146 1,127 1,068 1,208
Noncurrent Deferred & Refundable Income Taxes		 4.47 6.93 6.94 6.25 6.81 13 74 57 46 46 35
Other Noncurrent Operating Assets		 10 7.49 12 16 20 109 95 101 205 214 211
Total Liabilities & Shareholders' Equity		 1,587 1,774 1,808 3,211 3,108 3,303 3,615 3,782 3,890 3,782 4,037
Total Liabilities		 883 1,023 968 2,249 1,732 1,887 2,100 2,098 2,085 2,194 2,492
Total Current Liabilities		 126 139 124 349 263 331 401 340 321 307 922
Short-Term Debt		 3.75 14 0.00 83 23 45 146 45 38 15 607
Accounts Payable		 29 35 29 94 76 113 55 62 102 92 83
Accrued Expenses		 40 39 35 88 85 77 94 120 80 101 122
Current Employee Benefit Liabilities		 35 45 53 73 76 79 76 93 79 75 86
Other Current Liabilities		 - - - - - 12 13 20 22 24 25
Total Noncurrent Liabilities		 757 884 845 1,900 1,470 1,555 1,699 1,758 1,764 1,887 1,570
Long-Term Debt		 626 700 665 1,781 1,332 1,303 1,408 1,501 1,405 1,485 1,196
Capital Lease Obligations		 - - - - - - - 90 157 167 167
Noncurrent Deferred & Payable Income Tax Liabilities		 100 155 149 65 58 37 16 46 63 35 61
Other Noncurrent Operating Liabilities		 28 29 31 54 80 216 275 120 139 200 146
Total Equity & Noncontrolling Interests		 704 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545
Total Preferred & Common Equity		 704 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 704 751 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545
Common Stock		 780 1,021 799 823 1,193 1,215 1,292 1,266 1,278 1,303 1,324
Retained Earnings		 315 146 220 285 348 399 532 699 879 947 940
Treasury Stock		 -367 -367 -123 -122 -121 -120 -235 -234 -363 -647 -691
Accumulated Other Comprehensive Income / (Loss)		 -23 -48 -57 -24 -45 -76 -74 -45 10 -15 -28

Quarterly Balance Sheets for Integra LifeSciences

This table presents Integra LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 3,807 3,742 3,778 3,739 4,078 4,074 4,066
Total Current Assets		 1,196 1,029 1,051 1,027 1,416 1,112 1,100
Cash & Equivalents		 512 307 309 274 592 215 215
Short-Term Investments		 - - - - 71 82 62
Accounts Receivable		 248 254 259 256 241 271 248
Inventories, net		 311 351 354 366 403 422 437
Prepaid Expenses		 123 117 129 131 73 94 86
Other Current Assets		 1.83 - - - 35 29 50
Plant, Property, & Equipment, net		 301 315 318 319 345 374 391
Total Noncurrent Assets		 2,310 2,398 2,409 2,393 2,317 2,589 2,575
Goodwill		 978 1,042 1,043 1,036 1,040 1,105 1,117
Intangible Assets		 1,054 1,109 1,094 1,067 1,023 1,220 1,210
Noncurrent Deferred & Refundable Income Taxes		 52 45 56 56 34 46 49
Other Noncurrent Operating Assets		 226 203 216 235 220 218 200
Total Liabilities & Shareholders' Equity		 3,807 3,742 3,778 3,739 4,078 4,074 4,066
Total Liabilities		 2,083 2,067 2,094 2,160 2,480 2,540 2,544
Total Current Liabilities		 304 282 377 356 302 328 913
Short-Term Debt		 56 0.00 96 85 19 24 602
Accounts Payable		 81 113 100 94 94 107 78
Accrued Expenses		 79 93 95 90 112 102 132
Current Deferred Revenue		 6.36 - - - - - 9.99
Current Employee Benefit Liabilities		 69 54 65 64 53 70 76
Other Current Liabilities		 13 23 23 23 24 25 15
Total Noncurrent Liabilities		 1,778 1,785 1,717 1,804 2,178 2,212 1,632
Long-Term Debt		 1,487 1,440 1,333 1,420 1,837 1,801 1,205
Noncurrent Deferred & Payable Income Tax Liabilities		 70 62 71 74 31 87 69
Other Noncurrent Operating Liabilities		 221 127 153 142 140 155 358
Total Equity & Noncontrolling Interests		 1,724 1,675 1,683 1,579 1,598 1,534 1,522
Total Preferred & Common Equity		 1,724 1,675 1,683 1,579 1,598 1,534 1,522
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,724 1,675 1,683 1,579 1,598 1,534 1,522
Common Stock		 1,269 1,246 1,285 1,263 1,311 1,302 1,318
Retained Earnings		 826 903 908 927 944 931 920
Treasury Stock		 -363 -482 -514 -613 -646 -681 -692
Accumulated Other Comprehensive Income / (Loss)		 -7.44 7.07 4.83 1.75 -11 -19 -25

Annual Metrics and Ratios for Integra LifeSciences

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.33% 10.80% 12.39% 19.77% 23.92% 3.06% -9.60% 12.43% 0.99% -1.03% 4.47%
EBITDA Growth		 73.97% 24.86% 31.71% -27.99% 71.45% -7.68% 30.15% 33.20% -0.39% -34.99% -26.98%
EBIT Growth		 100.62% 24.95% 38.03% -60.28% 158.48% -13.42% 50.85% 65.81% -2.62% -54.19% -71.92%
NOPAT Growth		 30.32% -83.37% 958.51% 167.83% -53.86% -33.39% 176.73% -28.32% 29.83% -53.79% -78.66%
Net Income Growth		 261.41% -110.35% 2,218.90% -13.17% -6.09% -17.43% 166.71% 26.28% 6.79% -62.48% -110.25%
EPS Growth		 261.41% -110.35% 2,218.90% -12.77% -12.20% -19.44% 170.69% 26.11% 9.09% -61.11% -110.71%
Operating Cash Flow Growth		 56.88% 25.48% 11.02% -1.60% 74.33% 15.90% -11.93% 53.28% -15.35% -47.08% -7.55%
Free Cash Flow Firm Growth		 -356.94% -162.76% 135.50% -1,035.49% 117.88% -41.70% 222.20% -161.03% 129.98% 58.00% -386.75%
Invested Capital Growth		 17.91% 27.88% -0.79% 89.03% -2.27% -0.98% -4.56% 14.66% 5.01% -0.11% 10.07%
Revenue Q/Q Growth		 9.84% 11.13% 1.48% 10.50% 1.01% 0.78% -0.47% 1.11% -0.48% -0.06% 2.91%
EBITDA Q/Q Growth		 -12.71% 1.85% 9.58% -13.10% 11.57% 0.63% 5.78% 1.63% 4.12% -11.72% 2.96%
EBIT Q/Q Growth		 -33.50% -3.82% 16.43% -39.20% 24.82% 1.14% 12.21% 3.35% 3.85% -22.64% -4.23%
NOPAT Q/Q Growth		 -37.89% -43.89% 17.19% 244.04% -50.58% -17.25% 130.64% -24.43% 2.43% -24.94% -1.46%
Net Income Q/Q Growth		 11.09% -163.99% 21.64% 33.12% -24.02% -16.36% 137.12% -21.88% 4.37% -32.83% -6.11%
EPS Q/Q Growth		 11.09% -163.99% 21.64% 32.26% -23.40% -17.14% 134.33% -21.74% 4.85% -30.58% -12.50%
Operating Cash Flow Q/Q Growth		 18.70% 0.75% -14.10% 4.58% 18.48% 25.14% -4.19% -3.40% 6.46% -15.96% -5.83%
Free Cash Flow Firm Q/Q Growth		 26.97% -52.85% 82.82% -695.62% 123.51% 21.95% 5.26% -73.87% -58.35% 197.97% -433.12%
Invested Capital Q/Q Growth		 -5.41% 2.41% -0.07% 65.44% -0.20% -1.54% 2.77% 3.78% 6.99% -1.12% 6.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 61.98% 63.01% 64.81% 63.35% 61.19% 62.79% 62.03% 61.24% 62.29% 57.39% 54.77%
EBITDA Margin		 14.61% 16.46% 19.29% 11.60% 16.05% 14.37% 20.70% 24.52% 24.18% 15.89% 11.10%
Operating Margin		 8.52% 9.02% 11.63% 3.77% 7.54% 6.18% 11.03% 12.79% 15.34% 7.23% 1.76%
EBIT Margin		 8.46% 9.54% 11.71% 3.88% 8.10% 6.81% 11.36% 16.75% 16.15% 7.48% 2.01%
Profit (Net Income) Margin		 4.27% -0.40% 7.52% 5.45% 4.13% 3.31% 9.76% 10.96% 11.59% 4.39% -0.43%
Tax Burden Percent		 74.63% -5.80% 82.48% 568.67% 105.92% 83.52% 143.17% 78.76% 84.41% 83.56% 38.08%
Interest Burden Percent		 67.64% 72.08% 77.81% 24.67% 48.12% 58.19% 60.02% 83.10% 85.02% 70.35% -56.37%
Effective Tax Rate		 20.35% 88.71% 17.52% -468.67% -5.92% 16.48% -43.17% 21.24% 15.59% 16.44% 0.00%
Return on Invested Capital (ROIC)		 5.29% 0.71% 6.76% 12.57% 4.49% 3.04% 8.64% 5.91% 7.01% 3.16% 0.64%
ROIC Less NNEP Spread (ROIC-NNEP)		 -0.67% -1.64% 3.40% -4.31% 0.58% 0.66% 0.69% 7.25% 5.14% 1.13% -1.11%
Return on Net Nonoperating Assets (RNNOA)		 -0.33% -1.20% 2.62% -5.38% 0.72% 0.56% 0.49% 4.66% 3.34% 0.83% -1.09%
Return on Equity (ROE)		 4.96% -0.48% 9.37% 7.19% 5.20% 3.60% 9.13% 10.57% 10.35% 3.99% -0.44%
Cash Return on Invested Capital (CROIC)		 -11.15% -23.76% 7.54% -49.03% 6.78% 4.02% 13.31% -7.75% 2.12% 3.27% -8.94%
Operating Return on Assets (OROA)		 4.85% 5.01% 6.49% 1.84% 3.78% 3.22% 4.50% 6.98% 6.56% 3.00% 0.83%
Return on Assets (ROA)		 2.45% -0.21% 4.16% 2.58% 1.92% 1.57% 3.87% 4.57% 4.71% 1.77% -0.18%
Return on Common Equity (ROCE)		 4.96% -0.48% 9.37% 7.19% 5.20% 3.60% 9.13% 10.57% 10.35% 3.99% -0.44%
Return on Equity Simple (ROE_SIMPLE)		 4.83% -0.47% 8.88% 6.73% 4.42% 3.54% 8.84% 10.04% 10.01% 4.27% -0.45%
Net Operating Profit after Tax (NOPAT)		 54 8.99 95 255 118 78 217 155 202 93 20
NOPAT Margin		 6.78% 1.02% 9.59% 21.44% 7.98% 5.16% 15.80% 10.07% 12.95% 6.05% 1.23%
Net Nonoperating Expense Percent (NNEP)		 5.96% 2.35% 3.36% 16.88% 3.91% 2.38% 7.95% -1.34% 1.86% 2.03% 1.76%
Return On Investment Capital (ROIC_SIMPLE)		 4.05% 0.61% 6.32% 9.02% 4.31% 2.83% 7.06% 4.68% 5.92% 2.86% 0.57%
Cost of Revenue to Revenue		 38.02% 36.99% 35.19% 36.65% 38.81% 37.21% 37.97% 38.76% 37.71% 42.61% 45.23%
SG&A Expenses to Revenue		 47.14% 47.10% 45.93% 52.52% 46.91% 45.31% 43.34% 41.33% 39.57% 42.60% 44.52%
R&D to Revenue		 5.47% 5.77% 5.86% 5.34% 5.30% 9.52% 5.64% 6.03% 6.50% 6.76% 7.16%
Operating Expenses to Revenue		 53.46% 53.99% 53.19% 59.58% 53.65% 56.61% 51.00% 48.46% 46.95% 50.16% 53.00%
Earnings before Interest and Taxes (EBIT)		 67 84 116 46 119 103 156 258 252 115 32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 116 145 191 138 236 218 284 378 377 245 179
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.52 3.34 3.82 3.90 2.79 3.53 3.61 3.37 2.60 2.14 1.13
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.23 2.84 3.23 3.16 2.61 3.30 3.99 3.68 3.01 2.21 1.09
Price to Earnings (P/E)		 52.29 0.00 43.01 58.01 63.18 99.68 40.86 33.56 25.94 50.26 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.91% 0.00% 2.32% 1.72% 1.58% 1.00% 2.45% 2.98% 3.86% 1.99% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.11 2.24 2.69 2.05 1.95 2.40 2.68 2.42 1.98 1.62 1.06
Enterprise Value to Revenue (EV/Rev)		 2.93 3.59 3.80 4.58 3.43 4.05 4.78 4.41 3.74 3.09 2.14
Enterprise Value to EBITDA (EV/EBITDA)		 20.08 21.81 19.70 39.51 21.40 28.21 23.09 17.97 15.47 19.44 19.27
Enterprise Value to EBIT (EV/EBIT)		 34.68 37.65 32.45 117.99 42.39 59.58 42.07 26.31 23.16 41.32 106.52
Enterprise Value to NOPAT (EV/NOPAT)		 43.23 352.61 39.63 21.37 43.01 78.58 30.25 43.76 28.89 51.10 173.30
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.96 30.22 32.39 47.54 25.33 26.59 32.16 21.76 22.03 34.02 26.64
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 35.49 0.00 28.46 59.40 19.64 0.00 95.42 49.36 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.89 0.95 0.79 1.94 0.98 0.95 1.03 0.97 0.89 1.05 1.27
Long-Term Debt to Equity		 0.89 0.93 0.79 1.85 0.97 0.92 0.93 0.94 0.87 1.04 0.88
Financial Leverage		 0.49 0.73 0.77 1.25 1.24 0.85 0.71 0.64 0.65 0.74 0.97
Leverage Ratio		 2.03 2.31 2.25 2.79 2.70 2.30 2.36 2.31 2.20 2.26 2.50
Compound Leverage Factor		 1.37 1.66 1.75 0.69 1.30 1.34 1.42 1.92 1.87 1.59 -1.41
Debt to Total Capital		 47.21% 48.74% 44.20% 65.95% 49.60% 48.76% 50.65% 49.27% 47.01% 51.21% 56.04%
Short-Term Debt to Total Capital		 0.28% 0.98% 0.00% 2.93% 0.82% 1.63% 4.76% 1.35% 1.12% 0.45% 17.27%
Long-Term Debt to Total Capital		 46.93% 47.76% 44.20% 63.02% 48.78% 47.13% 45.88% 47.92% 45.89% 50.76% 38.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 52.79% 51.26% 55.80% 34.05% 50.40% 51.24% 49.35% 50.73% 52.99% 48.79% 43.96%
Debt to EBITDA		 5.41 4.92 3.47 13.52 5.73 6.18 5.48 4.33 4.25 6.80 11.02
Net Debt to EBITDA		 4.80 4.56 2.94 12.26 5.14 5.27 3.82 2.97 3.04 5.54 9.49
Long-Term Debt to EBITDA		 5.38 4.82 3.47 12.92 5.64 5.97 4.96 4.21 4.15 6.74 7.62
Debt to NOPAT		 11.66 79.50 6.99 7.32 11.52 17.21 7.17 10.54 7.94 17.88 99.06
Net Debt to NOPAT		 10.33 73.69 5.92 6.63 10.34 14.67 5.00 7.23 5.67 14.56 85.30
Long-Term Debt to NOPAT		 11.59 77.90 6.99 6.99 11.33 16.64 6.50 10.25 7.75 17.73 68.53
Altman Z-Score		 2.43 2.44 3.17 1.72 2.29 2.51 2.57 2.77 2.54 2.03 1.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.20 3.15 4.01 2.36 2.95 2.59 3.09 3.39 3.62 3.45 1.17
Quick Ratio		 1.45 1.30 2.02 1.22 1.54 1.43 1.73 2.19 2.24 1.85 0.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -114 -299 106 -994 178 104 334 -204 61 96 -277
Operating Cash Flow to CapEx		 217.96% 327.92% 247.61% 265.09% 258.26% 333.00% 578.53% 650.63% 847.71% 209.31% 123.91%
Free Cash Flow to Firm to Interest Expense		 -5.18 -12.72 4.12 -28.38 2.75 1.92 4.66 -4.04 1.23 1.88 -3.92
Operating Cash Flow to Interest Expense		 3.80 4.46 4.51 3.27 3.09 4.29 2.85 6.20 5.33 2.72 1.83
Operating Cash Flow Less CapEx to Interest Expense		 2.06 3.10 2.69 2.04 1.89 3.00 2.36 5.25 4.70 1.42 0.35
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.53 0.55 0.47 0.47 0.47 0.40 0.42 0.41 0.40 0.41
Accounts Receivable Turnover		 6.97 7.28 7.08 5.94 5.69 5.61 5.48 6.75 6.29 5.90 6.06
Inventory Turnover		 1.53 1.63 1.63 1.70 1.98 1.89 1.66 1.91 1.83 1.84 1.78
Fixed Asset Turnover		 4.04 4.43 4.64 4.83 5.17 4.76 4.39 5.15 5.00 4.73 4.32
Accounts Payable Turnover		 7.61 10.26 10.94 7.08 6.72 5.97 6.21 10.27 7.17 6.76 8.33
Days Sales Outstanding (DSO)		 52.35 50.17 51.59 61.43 64.15 65.06 66.63 54.11 58.03 61.89 60.25
Days Inventory Outstanding (DIO)		 238.59 223.87 224.12 215.22 184.16 192.75 219.41 191.57 199.47 198.44 205.11
Days Payable Outstanding (DPO)		 47.96 35.57 33.37 51.55 54.29 61.13 58.76 35.55 50.94 54.02 43.80
Cash Conversion Cycle (CCC)		 242.98 238.47 242.33 225.10 194.01 196.69 227.27 210.13 206.56 206.31 221.56
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,105 1,414 1,403 2,651 2,591 2,566 2,449 2,808 2,948 2,945 3,242
Invested Capital Turnover		 0.78 0.70 0.70 0.59 0.56 0.59 0.55 0.59 0.54 0.52 0.52
Increase / (Decrease) in Invested Capital		 168 308 -11 1,249 -60 -25 -117 359 141 -3.29 297
Enterprise Value (EV)		 2,336 3,169 3,770 5,445 5,057 6,153 6,555 6,797 5,827 4,762 3,447
Market Capitalization		 1,778 2,507 3,207 3,756 3,842 5,004 5,471 5,674 4,683 3,405 1,750
Book Value per Share		 $21.48 $20.32 $22.46 $12.26 $16.15 $16.50 $17.98 $19.89 $21.60 $20.31 $20.03
Tangible Book Value per Share		 ($2.19) ($9.86) ($6.21) ($14.47) ($7.40) ($6.63) ($4.83) ($5.60) ($4.32) ($6.85) ($9.84)
Total Capital		 1,334 1,466 1,505 2,826 2,730 2,765 3,069 3,321 3,405 3,254 3,515
Total Debt		 630 714 665 1,864 1,354 1,348 1,554 1,637 1,601 1,666 1,970
Total Long-Term Debt		 626 700 665 1,781 1,332 1,303 1,408 1,592 1,563 1,652 1,363
Net Debt		 558 662 563 1,689 1,215 1,149 1,084 1,123 1,144 1,357 1,696
Capital Expenditures (CapEx)		 38 32 47 43 77 70 35 48 31 67 104
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 335 262 270 381 396 373 512 345 422 456 493
Debt-free Net Working Capital (DFNWC)		 407 314 372 556 535 572 982 859 879 766 767
Net Working Capital (NWC)		 403 299 372 473 513 527 836 814 841 751 160
Net Nonoperating Expense (NNE)		 20 13 21 190 57 28 83 -14 21 25 27
Net Nonoperating Obligations (NNO)		 401 662 563 1,689 1,215 1,149 934 1,123 1,144 1,357 1,696
Total Depreciation and Amortization (D&A)		 49 61 75 92 117 115 128 120 125 130 146
Debt-free, Cash-free Net Working Capital to Revenue		 42.09% 29.63% 27.17% 32.07% 26.91% 24.58% 37.34% 22.38% 27.10% 29.61% 30.62%
Debt-free Net Working Capital to Revenue		 51.09% 35.54% 37.45% 46.79% 36.34% 37.68% 71.61% 55.67% 56.41% 49.66% 47.60%
Net Working Capital to Revenue		 50.62% 33.91% 37.45% 39.83% 34.81% 34.72% 60.95% 52.75% 53.96% 48.72% 9.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.47 ($0.05) $1.00 $0.84 $0.73 $0.59 $1.58 $2.00 $2.18 $0.85 ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 71.72M 68.99M 74.39M 76.90M 82.86M 85.64M 84.65M 84.70M 83.00M 80.09M 77.01M
Adjusted Diluted Earnings per Share		 $0.47 ($0.05) $0.94 $0.82 $0.72 $0.58 $1.57 $1.98 $2.16 $0.84 ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 72.89M 71.35M 79.19M 79.12M 84.00M 86.49M 85.23M 85.49M 83.52M 80.34M 77.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 72.48M 74.00M 74.82M 78.49M 85.23M 84.44M 84.37M 83.24M 81.64M 78.22M 77.22M
Normalized Net Operating Profit after Tax (NOPAT)		 54 56 95 31 78 78 106 155 202 93 20
Normalized NOPAT Margin		 6.78% 6.31% 9.59% 2.64% 5.28% 5.16% 7.72% 10.07% 12.95% 6.05% 1.23%
Pre Tax Income Margin		 5.72% 6.87% 9.11% 0.96% 3.90% 3.96% 6.82% 13.92% 13.73% 5.26% -1.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 3.07 3.58 4.50 1.32 1.84 1.91 2.18 5.13 5.07 2.24 0.46
NOPAT to Interest Expense		 2.46 0.38 3.69 7.28 1.82 1.45 3.03 3.08 4.07 1.81 0.28
EBIT Less CapEx to Interest Expense		 1.32 2.22 2.68 0.08 0.65 0.63 1.68 4.17 4.44 0.94 -1.02
NOPAT Less CapEx to Interest Expense		 0.72 -0.98 1.86 6.04 0.62 0.16 2.54 2.13 3.44 0.51 -1.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.69% 0.00% 69.23% 405.96% -755.63%

Quarterly Metrics and Ratios for Integra LifeSciences

This table displays calculated financial ratios and metrics derived from Integra LifeSciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -0.43% -1.85% 1.12% -4.16% -0.72% -0.25% -3.14% 9.68% -0.42% 11.49%
EBITDA Growth		 6.99% 10.48% -12.63% -52.11% -40.70% -31.57% -50.12% -17.83% -47.06% 7.30%
EBIT Growth		 11.68% 14.92% -23.84% -80.03% -60.40% -46.99% -91.12% -112.89% -122.31% -3.75%
NOPAT Growth		 14.96% 9.64% -23.38% -73.68% -49.55% -55.71% -90.63% -115.50% -120.48% 23.98%
Net Income Growth		 15.47% 16.66% -26.37% -90.66% -60.94% -62.54% -113.54% -396.41% -154.85% -2.02%
EPS Growth		 17.65% 18.87% -25.64% -90.74% -60.00% -58.73% -113.79% -420.00% -158.33% -3.85%
Operating Cash Flow Growth		 -17.48% 23.18% -41.02% -57.46% -60.81% -31.15% -39.76% 42.87% -16.01% -13.63%
Free Cash Flow Firm Growth		 101.80% 72.51% -171.52% -2,266.04% -4,040.08% 133.15% 103.36% -47.53% 60.07% -1,047.17%
Invested Capital Growth		 1.86% 5.01% 7.59% 7.16% 8.08% -0.11% -0.11% 9.10% 2.42% 10.07%
Revenue Q/Q Growth		 -3.17% 3.33% -4.32% 0.11% 0.30% 3.82% -7.09% 13.37% -8.93% 16.23%
EBITDA Q/Q Growth		 6.91% 3.45% -31.25% -37.01% 32.38% 19.38% -49.89% 3.76% -14.70% 141.92%
EBIT Q/Q Growth		 10.50% 5.05% -47.39% -67.31% 119.16% 40.63% -91.19% -147.47% -279.27% 706.67%
NOPAT Q/Q Growth		 6.22% 1.30% -47.09% -53.78% 103.65% -11.08% -88.80% -176.41% -169.07% 638.42%
Net Income Q/Q Growth		 11.45% 6.07% -54.24% -82.73% 365.99% 1.73% -116.54% -277.99% 13.76% 281.71%
EPS Q/Q Growth		 11.11% 5.00% -53.97% -82.76% 380.00% 8.33% -115.38% -300.00% 12.50% 278.57%
Operating Cash Flow Q/Q Growth		 2.76% 24.92% -69.35% 8.12% -5.34% 119.46% -73.18% 156.42% -44.35% 125.66%
Free Cash Flow Firm Q/Q Growth		 -41.85% -1,812.72% -112.08% -2.56% -5.77% 114.41% -78.48% -4,598.95% 71.37% -241.77%
Invested Capital Q/Q Growth		 -0.32% 6.99% 0.53% -0.06% 0.54% -1.12% 0.53% 9.16% -5.62% 6.27%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 61.46% 62.83% 61.15% 54.30% 57.10% 57.05% 56.07% 54.02% 52.58% 56.27%
EBITDA Margin		 25.85% 25.88% 18.59% 11.70% 15.44% 17.75% 9.57% 8.76% 8.21% 17.08%
Operating Margin		 16.89% 17.04% 9.55% 3.28% 6.95% 9.08% 1.07% -0.72% -2.14% 8.05%
EBIT Margin		 17.74% 18.04% 9.92% 3.24% 7.08% 9.59% 0.91% -0.38% -1.59% 8.28%
Profit (Net Income) Margin		 12.96% 13.30% 6.36% 1.10% 5.10% 5.00% -0.89% -2.97% -2.81% 4.39%
Tax Burden Percent		 84.90% 82.46% 81.36% 109.41% 104.77% 68.73% 62.73% 81.67% 52.52% 86.22%
Interest Burden Percent		 86.03% 89.44% 78.84% 30.97% 68.76% 75.82% -155.93% 953.83% 337.23% 61.53%
Effective Tax Rate		 15.10% 17.54% 18.64% -9.41% -4.77% 31.27% 0.00% 0.00% 0.00% 13.78%
Return on Invested Capital (ROIC)		 8.22% 7.61% 4.24% 1.94% 3.92% 3.26% 0.39% -0.26% -0.78% 3.61%
ROIC Less NNEP Spread (ROIC-NNEP)		 7.71% 7.34% 3.80% 1.14% 3.23% 2.87% -0.07% -0.95% -1.12% 2.87%
Return on Net Nonoperating Assets (RNNOA)		 4.84% 4.77% 2.81% 0.81% 2.38% 2.12% -0.06% -0.88% -1.06% 2.80%
Return on Equity (ROE)		 13.06% 12.38% 7.05% 2.75% 6.30% 5.38% 0.33% -1.13% -1.83% 6.41%
Cash Return on Invested Capital (CROIC)		 5.37% 2.12% -0.58% -1.59% -3.43% 3.27% 2.44% -6.91% -1.72% -8.94%
Operating Return on Assets (OROA)		 7.33% 7.32% 4.18% 1.33% 2.89% 3.85% 0.36% -0.15% -0.64% 3.41%
Return on Assets (ROA)		 5.35% 5.40% 2.68% 0.45% 2.08% 2.01% -0.35% -1.18% -1.13% 1.81%
Return on Common Equity (ROCE)		 13.06% 12.38% 7.05% 2.75% 6.30% 5.38% 0.33% -1.13% -1.83% 6.41%
Return on Equity Simple (ROE_SIMPLE)		 10.03% 0.00% 10.26% 7.80% 6.39% 0.00% 2.52% 1.54% -0.43% 0.00%
Net Operating Profit after Tax (NOPAT)		 55 56 30 14 28 25 2.77 -2.12 -5.71 31
NOPAT Margin		 14.34% 14.05% 7.77% 3.59% 7.29% 6.24% 0.75% -0.51% -1.50% 6.94%
Net Nonoperating Expense Percent (NNEP)		 0.50% 0.26% 0.44% 0.80% 0.69% 0.40% 0.46% 0.69% 0.34% 0.74%
Return On Investment Capital (ROIC_SIMPLE)		 1.69% 1.64% 0.90% 0.42% 0.86% 0.76% 0.08% -0.06% -0.17% 0.87%
Cost of Revenue to Revenue		 38.54% 37.17% 38.85% 45.70% 42.90% 42.95% 43.93% 45.98% 47.42% 43.73%
SG&A Expenses to Revenue		 37.34% 38.17% 43.76% 43.25% 42.35% 41.09% 44.95% 46.74% 46.53% 40.33%
R&D to Revenue		 6.42% 6.73% 7.02% 6.97% 6.95% 6.12% 7.31% 7.12% 7.20% 7.05%
Operating Expenses to Revenue		 44.57% 45.79% 51.59% 51.02% 50.14% 47.97% 55.00% 54.75% 54.72% 48.22%
Earnings before Interest and Taxes (EBIT)		 68 72 38 12 27 38 3.35 -1.59 -6.04 37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 100 103 71 45 59 70 35 37 31 76
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.05 2.60 2.80 2.00 1.97 2.14 1.73 1.50 0.93 1.13
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.26 3.01 3.00 2.18 2.02 2.21 1.81 1.47 0.90 1.09
Price to Earnings (P/E)		 20.45 25.94 27.27 25.66 30.83 50.26 68.88 97.10 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.89% 3.86% 3.67% 3.90% 3.24% 1.99% 1.45% 1.03% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.66 1.98 2.02 1.57 1.51 1.62 1.40 1.24 0.96 1.06
Enterprise Value to Revenue (EV/Rev)		 2.92 3.74 3.83 3.01 2.92 3.09 2.70 2.55 1.88 2.14
Enterprise Value to EBITDA (EV/EBITDA)		 12.63 15.47 16.31 14.62 16.25 19.44 19.74 19.82 16.92 19.27
Enterprise Value to EBIT (EV/EBIT)		 18.86 23.16 24.93 24.43 30.26 41.32 51.15 59.72 86.98 106.52
Enterprise Value to NOPAT (EV/NOPAT)		 23.21 28.89 31.01 30.51 36.31 51.10 59.83 71.87 145.61 173.30
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.39 22.03 24.26 22.34 27.07 34.02 31.91 28.19 21.39 26.64
Enterprise Value to Free Cash Flow (EV/FCFF)		 31.16 95.42 0.00 0.00 0.00 49.36 57.13 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.90 0.89 0.95 0.94 1.06 1.05 1.27 1.30 1.19 1.27
Long-Term Debt to Equity		 0.86 0.87 0.95 0.89 1.01 1.04 1.26 1.28 0.79 0.88
Financial Leverage		 0.63 0.65 0.74 0.71 0.74 0.74 0.81 0.93 0.94 0.97
Leverage Ratio		 2.26 2.20 2.25 2.25 2.28 2.26 2.39 2.44 2.52 2.50
Compound Leverage Factor		 1.94 1.97 1.78 0.70 1.57 1.71 -3.73 23.28 8.49 1.54
Debt to Total Capital		 47.23% 47.01% 48.80% 48.55% 51.44% 51.21% 55.91% 56.53% 54.28% 56.04%
Short-Term Debt to Total Capital		 1.72% 1.12% 0.00% 2.92% 2.63% 0.45% 0.53% 0.69% 18.07% 17.27%
Long-Term Debt to Total Capital		 45.51% 45.89% 48.80% 45.63% 48.82% 50.76% 55.37% 55.84% 36.21% 38.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 52.77% 52.99% 51.20% 51.45% 48.56% 48.79% 44.09% 43.47% 45.72% 43.96%
Debt to EBITDA		 4.27 4.25 4.36 5.00 6.03 6.80 9.67 9.90 10.40 11.02
Net Debt to EBITDA		 2.85 3.04 3.52 4.02 5.04 5.54 6.51 8.43 8.80 9.49
Long-Term Debt to EBITDA		 4.11 4.15 4.36 4.70 5.72 6.74 9.58 9.78 6.94 7.62
Debt to NOPAT		 7.84 7.94 8.28 10.43 13.48 17.88 29.32 35.89 89.51 99.06
Net Debt to NOPAT		 5.24 5.67 6.69 8.40 11.27 14.56 19.72 30.55 75.76 85.30
Long-Term Debt to NOPAT		 7.55 7.75 8.28 9.80 12.79 17.73 29.04 35.46 59.71 68.53
Altman Z-Score		 2.07 2.38 2.39 1.94 1.86 1.96 1.70 1.48 1.08 1.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.93 3.62 3.65 2.78 2.89 3.45 4.68 3.39 1.20 1.17
Quick Ratio		 2.50 2.24 1.99 1.50 1.49 1.85 2.99 1.73 0.58 0.59
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4.94 -85 -180 -184 -195 28 6.04 -272 -78 -266
Operating Cash Flow to CapEx		 746.18% 590.30% 190.86% 181.88% 204.69% 239.45% 101.88% 136.00% 75.85% 171.42%
Free Cash Flow to Firm to Interest Expense		 0.39 -6.57 -14.84 -14.77 -14.91 2.04 0.44 -14.57 -4.02 -14.00
Operating Cash Flow to Interest Expense		 5.33 6.62 2.16 2.27 2.05 4.27 1.16 2.17 1.16 2.67
Operating Cash Flow Less CapEx to Interest Expense		 4.62 5.50 1.03 1.02 1.05 2.49 0.02 0.57 -0.37 1.11
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.41 0.41 0.42 0.41 0.41 0.40 0.39 0.40 0.40 0.41
Accounts Receivable Turnover		 6.65 6.29 6.40 6.23 6.11 5.90 6.18 5.91 6.20 6.06
Inventory Turnover		 1.87 1.83 1.75 1.83 1.87 1.84 1.78 1.78 1.76 1.78
Fixed Asset Turnover		 5.26 5.00 5.00 4.99 4.98 4.73 4.63 4.53 4.41 4.32
Accounts Payable Turnover		 8.49 7.17 5.89 7.31 7.28 6.76 6.48 6.65 8.24 8.33
Days Sales Outstanding (DSO)		 54.86 58.03 57.02 58.58 59.69 61.89 59.07 61.72 58.84 60.25
Days Inventory Outstanding (DIO)		 195.54 199.47 209.14 198.99 194.90 198.44 205.29 205.59 207.79 205.11
Days Payable Outstanding (DPO)		 42.99 50.94 61.93 49.94 50.15 54.02 56.36 54.90 44.29 43.80
Cash Conversion Cycle (CCC)		 207.41 206.56 204.23 207.64 204.44 206.31 208.01 212.41 222.33 221.56
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2,756 2,948 2,964 2,963 2,979 2,945 2,961 3,232 3,051 3,242
Invested Capital Turnover		 0.57 0.54 0.55 0.54 0.54 0.52 0.52 0.51 0.52 0.52
Increase / (Decrease) in Invested Capital		 50 141 209 198 223 -3.29 -3.26 270 72 297
Enterprise Value (EV)		 4,569 5,827 5,976 4,648 4,508 4,762 4,134 3,994 2,939 3,447
Market Capitalization		 3,537 4,683 4,687 3,369 3,109 3,405 2,771 2,296 1,410 1,750
Book Value per Share		 $20.65 $21.60 $20.52 $20.55 $19.40 $20.31 $20.56 $19.47 $19.61 $20.03
Tangible Book Value per Share		 ($3.68) ($4.32) ($5.82) ($5.54) ($6.44) ($6.85) ($5.98) ($10.03) ($10.37) ($9.84)
Total Capital		 3,268 3,405 3,272 3,272 3,252 3,254 3,624 3,529 3,328 3,515
Total Debt		 1,543 1,601 1,597 1,589 1,673 1,666 2,026 1,995 1,807 1,970
Total Long-Term Debt		 1,487 1,563 1,597 1,493 1,588 1,652 2,007 1,971 1,205 1,363
Net Debt		 1,031 1,144 1,289 1,279 1,399 1,357 1,363 1,698 1,529 1,696
Capital Expenditures (CapEx)		 9.16 14 14 16 13 25 15 30 30 30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 436 422 440 460 483 456 470 511 511 493
Debt-free Net Working Capital (DFNWC)		 948 879 747 769 757 766 1,133 808 788 767
Net Working Capital (NWC)		 892 841 747 674 672 751 1,113 784 187 160
Net Nonoperating Expense (NNE)		 5.31 2.99 5.37 9.50 8.36 4.94 6.06 10 4.99 11
Net Nonoperating Obligations (NNO)		 1,031 1,144 1,289 1,279 1,399 1,357 1,363 1,698 1,529 1,696
Total Depreciation and Amortization (D&A)		 31 31 33 32 32 32 32 38 37 39
Debt-free, Cash-free Net Working Capital to Revenue		 27.88% 27.10% 28.16% 29.78% 31.32% 29.61% 30.70% 32.64% 32.64% 30.62%
Debt-free Net Working Capital to Revenue		 60.58% 56.41% 47.84% 49.79% 49.07% 49.66% 74.05% 51.59% 50.38% 47.60%
Net Working Capital to Revenue		 56.99% 53.96% 47.84% 43.60% 43.53% 48.72% 72.78% 50.05% 11.95% 9.91%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.60 $0.65 $0.30 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25
Adjusted Weighted Average Basic Shares Outstanding		 83.04M 83.00M 81.87M 80.97M 79.69M 80.09M 77.74M 77.41M 76.45M 77.01M
Adjusted Diluted Earnings per Share		 $0.60 $0.63 $0.29 $0.05 $0.24 $0.26 ($0.04) ($0.16) ($0.14) $0.25
Adjusted Weighted Average Diluted Shares Outstanding		 83.40M 83.52M 82.32M 81.15M 79.81M 80.34M 77.74M 77.41M 76.45M 77.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 83.52M 81.64M 81.90M 81.40M 78.18M 78.22M 78.80M 77.58M 77.16M 77.22M
Normalized Net Operating Profit after Tax (NOPAT)		 55 56 30 8.75 19 25 2.77 -2.12 -5.71 31
Normalized NOPAT Margin		 14.34% 14.05% 7.77% 2.30% 4.87% 6.24% 0.75% -0.51% -1.50% 6.94%
Pre Tax Income Margin		 15.26% 16.13% 7.82% 1.00% 4.87% 7.27% -1.42% -3.63% -5.35% 5.09%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 5.34 5.57 3.12 0.99 2.07 2.77 0.25 -0.09 -0.31 1.93
NOPAT to Interest Expense		 4.31 4.34 2.45 1.10 2.13 1.80 0.20 -0.11 -0.29 1.62
EBIT Less CapEx to Interest Expense		 4.62 4.45 1.99 -0.26 1.07 0.98 -0.89 -1.68 -1.84 0.37
NOPAT Less CapEx to Interest Expense		 3.60 3.22 1.31 -0.15 1.13 0.02 -0.93 -1.71 -1.82 0.06
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 72.26% 69.23% 87.27% 114.27% 272.67% 405.96% 310.68% 740.02% -764.06% -755.63%

Frequently Asked Questions About Integra LifeSciences' Financials

When does Integra LifeSciences's fiscal year end?

According to the most recent income statement we have on file, Integra LifeSciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Integra LifeSciences' net income changed over the last 10 years?

Integra LifeSciences' net income appears to be on an upward trend, with a most recent value of -$6.94 million in 2024, falling from $34.00 million in 2014. The previous period was $67.74 million in 2023. Find out what analysts predict for Integra LifeSciences in the coming months.

What is Integra LifeSciences's operating income?
Integra LifeSciences's total operating income in 2024 was $28.41 million, based on the following breakdown:
  • Total Gross Profit: $882.06 million
  • Total Operating Expenses: $853.65 million
How has Integra LifeSciences revenue changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' total revenue changed from $796.72 million in 2014 to $1.61 billion in 2024, a change of 102.1%.

How much debt does Integra LifeSciences have?

Integra LifeSciences' total liabilities were at $2.49 billion at the end of 2024, a 13.6% increase from 2023, and a 182.2% increase since 2014.

How much cash does Integra LifeSciences have?

In the past 10 years, Integra LifeSciences' cash and equivalents has ranged from $48.13 million in 2015 to $513.45 million in 2021, and is currently $246.38 million as of their latest financial filing in 2024.

How has Integra LifeSciences' book value per share changed over the last 10 years?

Over the last 10 years, Integra LifeSciences' book value per share changed from 21.48 in 2014 to 20.03 in 2024, a change of -6.8%.


Related Companies

This page (NASDAQ:IART) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Trump Orders 'National Digital Asset Stockpile'
Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...
Crypto 101 Media | Sponsored
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...
Brownstone Research | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored